A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs BMS 906024 (Primary) ; Carboplatin; Fluorouracil; Folinic acid; Irinotecan; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 17 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
- 22 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.